반응식
Cl.[NH:2]1[CH2:7][CH2:6][C:5](=[CH:8][C:9]2[CH:10]=[C:11]([CH:23]=[CH:24][CH:25]=2)[O:12][C:13]2[CH:18]=[CH:17][C:16]([C:19]([F:22])([F:21])[F:20])=[CH:15][N:14]=2)[CH2:4][CH2:3]1.[CH3:26][C:27]1[N:32]=[CH:31][C:30]([NH:33][C:34](=O)[O:35]C2C=CC=CC=2)=[CH:29][CH:28]=1.NC1C=NC(C)=CC=1>>[CH3:26][C:27]1[N:32]=[CH:31][C:30]([NH:33][C:34]([N:2]2[CH2:7][CH2:6][C:5](=[CH:8][C:9]3[CH:25]=[CH:24][CH:23]=[C:11]([O:12][C:13]4[CH:18]=[CH:17][C:16]([C:19]([F:22])([F:20])[F:21])=[CH:15][N:14]=4)[CH:10]=3)[CH2:4][CH2:3]2)=[O:35])=[CH:29][CH:28]=1참가 물질
실험 절차
Following the procedure in Example 1, Step 6, 2-(3-piperidin-4-ylidenemethyl-phenoxy)-5-trifluoromethyl-pyridine hydrochloride (150 mg, 0.40 mmol, from Example 1, Step 5) and phenyl 6-methylpyridin-3-ylcarbamate (92 mg, 0.40 mmol, prepared according to the procedure described in Synthesis, 1997, 1189-1194 from 3-amino-6-methylpyridine, 3B Medical Systems, Inc.) were used to provide the title compound (184 mg). MS (APCI 10V) AP+ 469.3, AP− 467.2, 448.2; 1H NMR (400 MHz, CD3OD) δ ppm 2.41-2.44 (m, 2H) 2.46 (s, 3H) 2.58 (td, J=5.80, 0.83 Hz, 2H) 3.51-3.57 (m, 2H) 3.60-3.67 (m, 2H) 6.45 (s, 1H) 6.97-7.05 (m, 2H) 7.09-7.17 (m, 2H) 7.20 (d, J=8.50 Hz, 1H) 7.40 (td, J=7.70, 0.78 Hz, 1H) 7.77 (dd, J=8.37, 2.52 Hz, 1H) 8.08 (ddd, J=8.71, 2.56, 0.50 Hz, 1H) 8.42 (d, J=0.54 Hz, 1H) 8.43 (s, 1H).
후처리
- customprepared
출처 및 근거
- ORD 기록
- ord-cb290673ec314c9aadd176afa1ee1e75
- 출처 데이터셋
- uspto-grants-2011_10
- 특허 번호
- US08044052B2
연결된 노트
불러오는 중…